In March 1 Journal of Clinical Investigation Thomas Zollner and colleagues from JW Goethe University of Frankfurt, Germany, show that proteasome inhibition reduces superantigen-mediated T cell ...
The researchers administered mice biotin-epoxomicin, a cell membrane-impermeable proteasome inhibitor that inhibits ... are used to treat specific cancers. Villalón Landeros and Margolis intend ...
Sanofi's Sarclisa Gets First Approval In China For Relapsed Or Refractory Multiple Myeloma In Adults
including lenalidomide and a proteasome inhibitor. Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct ...
China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...
Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback